Unlocking Hope for Cancer Patients Using PDT
.
PETER MAC COMBINATION ICI AND INV043 STUDY
STUDY DESIGN
The study was conducted by Peter Mac using immune competent anal squamous cell carcinoma
(ASCC) in vivo models
INV043 was topically applied to 6-8 week old C57BL/6 mice followed 3 hours later with 71 J/cm2 of 660nm
light on Day 0 and Day 3. On Days 2, 6, 10 and 14 PD-1 was administered by intraosseous infusion as per
the below schematic diagram
⚫ Peter Mac generated an anal SCC line using a transgenic mouse model (CE cell line)
Four groups: Combination INV043 + Anti-PD-1, INV043 alone, Anti-PD-1 alone, control (n=8-10/group)
5x106 mouse SCC cells
(sub cut injection)
3hr + Light
INV043
topical
3hr + Light
10 #1ip
INV043
topical
21
10 #2ip
Day 6
10 #3ip
Day 10
10 #4ip
Day 14
Day 60
Day 0 Day 1 Day 2 Day 3 Day 4
Tumour size
200mm³
Tumour growth measurement/ health monitoring
6-8 weeks old
C57BL/6
Experimental endpoint: Day 60 post
treatment or humane endpoint: until
tumour size ≥1500mm³
INVIONView entire presentation